Print Page  Close Window
Receive E-mail AlertsE-mail Alerts
Keyword Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
03/28/17Alnylam to Webcast Presentation at 16th Annual Needham Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 28, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 11:20 am ET at the Westin Grand Central Hotel in New York City. A live audio webcast of the presentation will be available on the Investors section of the c... 
Printer Friendly Version
03/01/17Alnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 1, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) has granted access to its Priority Medicines (PRIME) scheme for givosiran (ALN-AS1), an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyrias. The purpose of the PRIME initiative is to b... 
Printer Friendly Version
02/28/17Alnylam Acknowledges Rare Disease Day by Highlighting Services to Aid in Rare Disease Diagnosis
– Alnylam Act™ sponsors free third-party genetic counseling and testing services for people at risk for hereditary ATTR amyloidosis (hATTR amyloidosis) – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 28, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today marked the 10th annual Rare Disease Day by underscoring its commitment to enabling diagnosis for people and caregivers impacted by specific rare ... 
Printer Friendly Version
02/27/17Alnylam to Webcast Presentations at Upcoming March Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 27, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the Cowen and Company 37th Annual Healthcare Conference on Monday, March 6, 2017 at 2:40 pm ET at the Boston Marriott Copley Place Hotel in Boston, Massachusetts and at the Barclays Global Healthcare Conference on Tuesday, March 14, 2017 at 9:30 am ... 
Printer Friendly Version
02/10/17Alnylam Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 10, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that the compensation committee of Alnylam's board of directors, which is composed entirely of independent directors, approved a grant, effective as of February 6, 2017, to a vice president level employee of the Company, of a non-qualified stock option to purchase 50,000 shares of Alnylam's common s... 
Printer Friendly Version
02/07/17Alnylam to Webcast Presentation at Leerink Partners 6th Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 7, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15, 2017 at 2:30 pm ET at the Lotte New York Palace Hotel in New York City. A live audio webcast of the presentation will be available on the Investor... 
Printer Friendly Version
02/02/17Alnylam Presents New Data on Fitusiran at EAHAD
– New Phase 1 Results Demonstrate Effective Bleed Management with Replacement Factor and Bypassing Agents During Fitusiran Administration – – Stability Study Results Support a Greater than Two Year Product Shelf-Life at Room Temperature Storage Conditions – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 2, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company today announced new results from... 
Printer Friendly Version
02/01/17Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2016 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2016 on Wednesday, February 8, 2017, after the U.S. financial markets close. Management will provide an update on the company and discuss fourth quarter and year-end 2016 results as well as expectations... 
Printer Friendly Version
01/03/17Alnylam to Webcast Presentation at 35th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 at 9:00 am PT (12:00 pm ET) at The Westin St. Francis in San Francisco. In addition, the company will webcast the Q&A breakout session immediately following its present... 
Printer Friendly Version
01/03/17Alnylam Announces Management Change and Key Promotion
– Company Announces Departure of Chief Business Officer and Promotion of Pushkal Garg, M.D., to Chief Medical Officer – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that David-Alexandre "DA" Gros, M.D., Senior Vice President and Chief Business Officer, plans to leave the company for personal reasons. His resignation will be effective... 
Printer Friendly Version

This part of our website contains archived information which should not be considered current and may no longer be accurate.